A Nutraceutical Formulation Improves Cardiometabolic Parameters in Obese/Overweight Subjects

Abstract

Obesity is a growing epidemic worldwide and is an independent risk factor for diabetes and cardiovascular disease. GlycaCare™ ‐Plus is a novel proprietary dietary formulation comprising Pterocarpus masupium extract, cinnamon extract, biotin, piperine, magnesium fumarate, zinc monomethionine, copper lysine, chromium polynicotinate and bimaltoxovanadium.The objective of this study was to evaluate the effect of GlycaCare™‐Plus on glucose tolerance and cardiometabolic parameters in a randomized, double blind, placebo‐controlled study.MethodsOverweight or obese subjects (n=21) were randomly assigned to receive either GlycaCareTM Plus oral (500 mg/day) or placebo (microcrystalline cellulose), twice daily, for 90 days. Multiple endpoints including blood pressure, body weight, oral glucose‐tolerance test, serum glucose, insulin, lipid profile, body‐fat distribution, serum markers of inflammation (C‐reactive peptide, interleukin‐6), and serum oxidative stress (8‐isoprostane) were assessed at baseline and after 90‐days following treatment. Subjects receiving GlyacaCare™‐Plus supplement exhibited attenuated insulin resistance as and attenuation of serum oxidative stress compared to those that received placebo, as evidenced by a reduction in HOMA‐IR and serum 8‐isprostane levels respectively in subjects. The supplement did not alter body mass, fat distribution, inflammatory parameters, serum lipids or glucose disposal.ConclusionPreliminary studies demonstrate that GlyacaCare™‐Plus supplement alleviates insulin resistance and reduces plasma oxidative stress in overweight/obese subjects.Support or Funding InformationFunded by a research grant from Sabinsa Corporation, New Jersey.